Abstract
ObjectiveSalivary gland cancers (SGC) are rare cancers with currently no standard treatment for recurrent/metastatic disease. Based on checkpoint inhibitors benefit in a broad range of tumours, NIvolumab in Salivary gland...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have